CO2022017764A2 - Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita - Google Patents
Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénitaInfo
- Publication number
- CO2022017764A2 CO2022017764A2 CONC2022/0017764A CO2022017764A CO2022017764A2 CO 2022017764 A2 CO2022017764 A2 CO 2022017764A2 CO 2022017764 A CO2022017764 A CO 2022017764A CO 2022017764 A2 CO2022017764 A2 CO 2022017764A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- receptor antagonist
- adrenal hyperplasia
- congenital adrenal
- crf1 receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan métodos relacionados con el tratamiento de la hiperplasia suprarrenal congénita en un sujeto que lo necesite que comprenden la administración al sujeto de un compuesto de Fórmula (I): o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2006039 | 2020-06-10 | ||
PCT/US2021/036668 WO2021252669A1 (en) | 2020-06-10 | 2021-06-09 | Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022017764A2 true CO2022017764A2 (es) | 2023-04-27 |
Family
ID=76744954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0017764A CO2022017764A2 (es) | 2020-06-10 | 2022-12-07 | Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita |
Country Status (20)
Country | Link |
---|---|
US (1) | US20230255942A1 (es) |
EP (1) | EP4164636A1 (es) |
JP (1) | JP2023531164A (es) |
KR (1) | KR20230038458A (es) |
CN (1) | CN116096373A (es) |
AU (1) | AU2021286565A1 (es) |
BR (1) | BR112022024875A2 (es) |
CA (1) | CA3181084A1 (es) |
CL (1) | CL2022003437A1 (es) |
CO (1) | CO2022017764A2 (es) |
CR (1) | CR20220624A (es) |
DO (1) | DOP2022000277A (es) |
EC (1) | ECSP22092977A (es) |
IL (1) | IL298901A (es) |
JO (1) | JOP20220329A1 (es) |
MA (1) | MA58993A1 (es) |
MX (1) | MX2022015159A (es) |
PE (1) | PE20240544A1 (es) |
TW (1) | TW202214235A (es) |
WO (1) | WO2021252669A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6585625B2 (ja) | 2014-01-21 | 2019-10-02 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 先天性副腎皮質過形成の処置のためのcrf1レセプターアンタゴニスト |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2796380B3 (fr) | 1999-07-15 | 2001-08-17 | Sanofi Synthelabo | Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant |
HUP0900267A2 (en) | 2009-04-30 | 2011-03-28 | Sanofi Aventis | Process for preparing of thiazole amines and intermediates thereof |
JP6585625B2 (ja) * | 2014-01-21 | 2019-10-02 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 先天性副腎皮質過形成の処置のためのcrf1レセプターアンタゴニスト |
JP7238130B2 (ja) * | 2018-12-07 | 2023-03-13 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 先天性副腎過形成を処置するためのcrf1受容体アンタゴニスト、その医薬製剤および固体形態 |
-
2021
- 2021-06-09 US US18/009,537 patent/US20230255942A1/en active Pending
- 2021-06-09 CA CA3181084A patent/CA3181084A1/en active Pending
- 2021-06-09 JP JP2022576006A patent/JP2023531164A/ja active Pending
- 2021-06-09 BR BR112022024875A patent/BR112022024875A2/pt unknown
- 2021-06-09 CR CR20220624A patent/CR20220624A/es unknown
- 2021-06-09 CN CN202180055808.8A patent/CN116096373A/zh active Pending
- 2021-06-09 MA MA58993A patent/MA58993A1/fr unknown
- 2021-06-09 AU AU2021286565A patent/AU2021286565A1/en active Pending
- 2021-06-09 IL IL298901A patent/IL298901A/en unknown
- 2021-06-09 TW TW110120961A patent/TW202214235A/zh unknown
- 2021-06-09 WO PCT/US2021/036668 patent/WO2021252669A1/en active Application Filing
- 2021-06-09 JO JOP/2022/0329A patent/JOP20220329A1/ar unknown
- 2021-06-09 MX MX2022015159A patent/MX2022015159A/es unknown
- 2021-06-09 PE PE2022002881A patent/PE20240544A1/es unknown
- 2021-06-09 EP EP21737274.7A patent/EP4164636A1/en active Pending
- 2021-06-09 KR KR1020237000553A patent/KR20230038458A/ko unknown
-
2022
- 2022-12-05 CL CL2022003437A patent/CL2022003437A1/es unknown
- 2022-12-07 CO CONC2022/0017764A patent/CO2022017764A2/es unknown
- 2022-12-07 DO DO2022000277A patent/DOP2022000277A/es unknown
- 2022-12-07 EC ECSENADI202292977A patent/ECSP22092977A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021286565A1 (en) | 2023-02-02 |
CR20220624A (es) | 2023-07-06 |
ECSP22092977A (es) | 2023-03-31 |
BR112022024875A2 (pt) | 2022-12-27 |
DOP2022000277A (es) | 2023-04-16 |
MX2022015159A (es) | 2023-03-01 |
WO2021252669A1 (en) | 2021-12-16 |
PE20240544A1 (es) | 2024-03-19 |
CL2022003437A1 (es) | 2023-05-26 |
EP4164636A1 (en) | 2023-04-19 |
US20230255942A1 (en) | 2023-08-17 |
CN116096373A (zh) | 2023-05-09 |
CA3181084A1 (en) | 2021-12-16 |
KR20230038458A (ko) | 2023-03-20 |
JP2023531164A (ja) | 2023-07-21 |
MA58993A1 (fr) | 2023-09-27 |
JOP20220329A1 (ar) | 2023-01-30 |
IL298901A (en) | 2023-02-01 |
TW202214235A (zh) | 2022-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20067394A (es) | Inhibidores de cinasa dependientes de ciclina | |
DOP2019000201A (es) | Compuestos inhibidores del vih | |
CO2020004301A2 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih | |
AR118707A1 (es) | Inhibidores de la proteasa del vih | |
BR112017017135A2 (pt) | inibidores de tgf-beta | |
PE20181778A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue | |
AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
PE20160180A1 (es) | Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos. | |
CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
DOP2021000077A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
ECSP109897A (es) | Composiciones terapeuticas y usos de las mismas | |
AR108461A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
CO2022017764A2 (es) | Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita | |
DOP2022000130A (es) | Derivados de benzimidazol | |
CO2017005806A2 (es) | Nuevos derivados de bencimidazol como agentes antihistamínicos | |
EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
CO2023001407A2 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
AR093851A1 (es) | Metodos para tratar la diabetes administrando un antagonista del receptor de glucagon en combinacion con un inhibidor de la absorcion del colesterol, combinacion | |
DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
EA201990766A1 (ru) | Индазольные соединения для применения при повреждениях сухожилий и/или связок | |
UY39625A (es) | Derivados tricíclicos útiles como inhibidores de parp7 | |
CL2022002817A1 (es) | Inhibidores de replicación del virus de inmunodeficiencia humana |